← Back to Clinical Trials
Recruiting NCT04240561

NCT04240561 Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04240561
Status Recruiting
Phase
Sponsor Northwestern University
Condition Hearing Loss, Sensorineural
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2021-07-01
Primary Completion 2027-08-31

Trial Parameters

Condition Hearing Loss, Sensorineural
Sponsor Northwestern University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 20
Sex ALL
Min Age 50 Years
Max Age 90 Years
Start Date 2021-07-01
Completion 2027-08-31
Interventions
High level of signal manipulationLow level of signal manipulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This current translational project, funded by NIH, aims to better understand the impact of various signal modification strategies for older adults with Alzheimer's dementia and its potential precursor, known as amnestic mild cognitive impairment. The investigators hypothesize that adults with Alzheimer's dementia represent an extreme case of restricted cognitive ability, such that very low working memory capacity and overall reduced cognitive capacity will limit benefit from advanced signal processing. Thus, the investigators hypothesize that adults with Alzheimer's dementia will receive greater benefit from acoustically simple, high-fidelity hearing aid processing that minimally alters the acoustic signal.

Eligibility Criteria

Inclusion Criteria: 1. Speak English as their primary language 2. Normal or corrected to normal vision (20/40 binocular vision or unaided using a Snellen chart) 3. Sensorineural hearing loss with pure-tone thresholds 25-70 dB HL at octave frequencies between 500 and 3000 Hz and a 4 frequency (.5, 1, 2, 3 kHz) pure-tone average of greater than or equal to 30 dB in each ear 4. Clinical Dementia Rating (CDR) of 0.5 or 1 (indicating slight or mild cognitive impairment in the areas of memory, orientation, judgment/problem solving, community affairs, behavior at home/hobbies, and personal care) 5. Diagnosis of dementia Alzheimer's type or amnestic mild cognitive impairment (minimum MoCA score of 18). 6. Living at home 7. Minimum Grade 10 education 8. Able to provide own consent as evaluated by the Consent Assessment. Exclusion Criteria: 1. Clinically significant unstable or progressive medical conditions, or conditions which, in the opinion of the investigator(s) places the participant at un

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology